People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Biotechnology, Biotech / Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2014 |
| Wheeler Bio, Inc. | — | Biotech / Pharma | Series B | $59.9M | $123.8M | 2021 |
| Vernal Biosciences, Inc. | — | Biotechnology | Series C | $42.5M | $828.0M | 2021 |
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2013 |
| Angiex, Inc. | — | Biotechnology | Series B | $24.9M | $98.6M | 2025 |
| Mytide Therapeutics, Inc. | — | Biotechnology | Series A | $8.2M | $12.7M | 2021 |
| Cantai Therapeutics, Inc. | — | Biotechnology | Seed | $4.3M | $6.2M | 2023 |
| Aakha Biologics, Inc. | — | Biotechnology | Pre-Seed | $750K | $3.5M | 2024 |
Errik Anderson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Errik Anderson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Philip Ferneau | 2 | 6 |
| Jonathan Sheller | 2 | 2 |
| Carl Gordon | 1 | 24 |
| David Anderson | 1 | 21 |
| Michael Ross | 1 | 18 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Jonathan Adams | 1 | 7 |
| Geeta Vemuri | 1 | 7 |
| Ian Ratcliffe | 1 | 6 |
| Philip J. Ferneau | 1 | 6 |
| Claudio Nessi | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Iain Dukes | 1 | 5 |
| Jason Camm | 1 | 5 |
| Errik B. Anderson | 1 | 5 |
| Jason Norris | 1 | 5 |
| Thomas Schuetz | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.